Incidence and spectrum of infections among HIV/AIDS patients with lymphoma during chemotherapy-Reference-Cited by-同舟云学术

Incidence and spectrum of infections among HIV/AIDS patients with lymphoma during chemotherapy

Published:2021-10 Issue:10 Volume:27 Page:1459-1464
ISSN:1341-321X
Container-title:Journal of Infection and Chemotherapy
language:en
Short-container-title:Journal of Infection and Chemotherapy

Author:

Wang Zhenyan^ORCID,Zhang Renfang,Liu Li,Shen Yinzhong,Chen Jun,Qi Tangkai,Song Wei,Tang Yang,Sun Jianjun,Lin Yixiao,Xu Shuibao,Yang Junyang,Lu Hongzhou

Funder

Shanghai Municipal Commission of Health and Family Planning

Publisher

Elsevier BV

Subject

Infectious Diseases,Pharmacology (medical),Microbiology (medical)

Reference14 articles.

1. Cancer risk in HIV-infected people in the USA from 1996 to 2012: a population-based, registry-linkage study;Hernández-Ramírez;Lancet HIV,2017

2. Projected cancer incidence rates and burden of incident cancer cases in HIV-infected adults in the United States through 2030;Shiels;Ann Intern Med,2018

3. Treatment factors affecting outcomes in HIV-associated non-Hodgkin lymphomas: a pooled analysis of 1546 patients;Barta;Blood,2013

4. B-cell lymphomas, version 1.2020. NCCN clinical practice guidelines in oncology.

5. Opportunistic infection and immunologic function in patients with human immunodeficiency virus- associated non-Hodgkin’s lymphoma treated with chemotherapy;Sparano;J Natl Cancer Inst,1997

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of HIV status on prognosis of malignancies among people living with HIV in Japan;Cancer;2024-05-08

2. Long-Term Survival Rates and Treatment Trends of Burkitt Lymphoma in Patients with HIV—A National Cancer Database (NCDB) Study;Cancers;2024-04-02

3. Readmission rates in HIV-associated burkitt lymphoma patients in the USA: a nationwide readmission database (NRD) analysis;AIDS Research and Therapy;2023-11-11

4. Readmission rates in HIV-associated Burkitt lymphoma patients: A nationwide readmission database (NRD) analysis;2023-08-23

5. Zanubrutinib, lenalidomide, and rituximab (ZR2 regimen) for HIV-associated diffuse large B-cell lymphoma: a real-world analysis from China;AIDS;2023-07-03